{
    "nctId": "NCT05905939",
    "briefTitle": "HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia",
    "officialTitle": "A Multicenter Observational Retrospective Study of Therapeutic Approaches and Clinical Outcomes in Real Clinical Practice in Russian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 755,
    "primaryOutcomeMeasure": "To describe the clinical and demographic profiles of patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in the Russian Federation",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with HER2-positive mBC who are receiving or have started any anti-HER2 therapy (except for trastuzumab deruxtecan) at the time of inclusion;\n* The diagnosis of mBC was established between the 1st July 2021 and the 1st July 2022;\n* Patients with the availability of at least 12 months of follow-up data (from the index data) in the medical records at the participating site, unless patient died within the first 12 months of diagnosis;\n* Age \u2265 18 years at the time of inclusion.\n\nExclusion Criteria:\n\n* Presence of other malignancies within period since diagnosis until the timepoint of data collection;\n* Patients receiving trastuzumab deruxtecan currently or in the anamnesis;\n* The participation in any randomized controlled trial within period since diagnosis until end of study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}